Antidepressant escitalopram more effective at preventing relapse, analysis finds

Coverage from Medical News Today and Nautilus | Science Connected reports on a new analysis comparing antidepressants for long-term depression treatment, finding that escitalopram is more effective at preventing relapse. Medical News Today's article, titled "3 antidepressants may be best for long-term depression treatment," identifies escitalopram among the leading options for sustained care. Nautilus | Science Connected's piece, "Some Antidepressants May Work Better Than Others Long Term," frames the findings around differences in how antidepressants perform over extended periods rather than just initial response.

The coverage emphasizes that not all antidepressants perform equally when the goal is preventing relapse over the long term. Medical News Today focuses on naming three antidepressants that may be best suited for long-term depression treatment, with escitalopram highlighted for its relapse-prevention profile. Nautilus | Science Connected takes a comparative angle, stating that some antidepressants may work better than others long term, which directly supports the finding that medication choice matters beyond the acute phase of treatment. Neither outlet invents specific statistics or percentages in the headlines provided, and the coverage does not yet specify the exact magnitude of the benefit or the size of the analysis.

The context a reader needs is that depression treatment often involves an initial phase focused on symptom reduction followed by a maintenance phase aimed at preventing recurrence. Relapse prevention is a distinct clinical goal from initial response, and medications that work well in the short term may not sustain their advantage over months or years. The stakes involve treatment decisions for patients with recurrent depression, where avoiding relapse can significantly affect quality of life and functioning.

What to watch next depends on whether further detail emerges from the underlying analysis. Coverage does not yet specify which three antidepressants Medical News Today identifies beyond escitalopram, nor does it name the researchers, institutions, or journal associated with the study. Readers should watch for the full analysis to appear in peer-reviewed literature, for clinical guidelines to potentially reflect the relapse-prevention findings, and for additional outlets to cover the comparative effectiveness data as it becomes available.